XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.21.2

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders | 9 Months Ended
--- | ---
Sep. 30, 2021
Earnings Per Share [Abstract] |
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders |
1 2. | Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders
The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the three and nine months ended September 30, 2021 and 2020, respectively (in thousands, except share and per share amounts):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Net loss attributable to Adaptive Biotechnologies Corporation |  | $ | (55,903 | ) |  | $ | (36,719 | ) |  | $ | (145,846 | ) |  | $ | (101,657 | )
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  |  | 140,833,564 |  |  |  | 134,372,026 |  |  |  | 140,060,379 |  |  |  | 129,289,948 |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  | $ | (0.40 | ) |  | $ | (0.27 | ) |  | $ | (1.04 | ) |  | $ | (0.79 | )
Since we were in a loss position for all periods presented, basic net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders is the same as diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the three and nine months ended September 30, 2021 and 2020, respectively, as they had an anti-dilutive effect:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Stock options issued and outstanding |  |  | 12,901,028 |  |  |  | 15,718,821 |  |  |  | 13,205,328 |  |  |  | 16,484,334 |
Nonvested restricted stock units |  |  | 795,469 |  |  |  | 50,000 |  |  |  | 572,194 |  |  |  | 34,138 |
Common stock warrant |  |  | — |  |  |  | 56,875 |  |  |  | 11,458 |  |  |  | 56,875 |
Total |  |  | 13,696,497 |  |  |  | 15,825,696 |  |  |  | 13,788,980 |  |  |  | 16,575,347 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration